CJC-1295 (no DAC) Research Sourcing Guide: practical notes on ordering CJC-1295 (no DAC) (5mg / 10mg) for Growth Research work through sulanpeptide.vip.
CJC-1295 (no DAC), also known as modified GRF (1-29), is a synthetic GHRH analog peptide used in laboratory research on growth-hormone-axis signaling, receptor activation, and short-acting peptide analog behavior without DAC-mediated albumin binding.
Modified GRF(1-29) without DAC preserves shorter half-life suitable for pulse-mimicking perfusion experiments on pituitary cells. Structure–activity studies compare amino-acid substitutions at positions 1–29 for GHRH receptor selectivity versus other class B GPCRs.
Perifusion systems measuring GH burst amplitude and frequency are widely cited when evaluating non-DAC GHRH analogs. Growth-axis research differentiates DAC and non-DAC formats when designing experiments that require discrete GH pulses versus sustained elevation models.
Sourcing steps: Open CJC-1295 (no DAC) under Growth Research on sulanpeptide.vip. Confirm 5mg / 10mg, Cat No., and any published COA before requisition. Quote requests should state quantity, destination country, and product URL. Contact Sulan Peptide Official at sales@sulanpeptide.vip or WhatsApp +447599352109.
Repeat orders for CJC-1295 (no DAC) should cite prior lot numbers when batch continuity matters across study phases.
Storage guidance for CJC-1295 (no DAC): Store at -20°C, in a cool and dry place. On receipt, log lot number, date, and freezer shelf; plan aliquots before first reconstitution.
Listed formats for CJC-1295 (no DAC): 5mg10vials, 10mg10vials. Quote emails should include Cat No. (CND5, CND10) so delivered vials match protocol design.
Literature searches should include CAS numbers alongside trade names for CJC-1295 (no DAC) to capture mechanism papers.
Pilot runs with CJC-1295 (no DAC) often use one catalog strength (5mg / 10mg) before scaling quantity for full cohorts.
Qualified Growth Research laboratories often maintain approved-supplier lists with scored criteria: specification clarity, COA quality, quote accuracy, and RUO labeling. CJC-1295 (no DAC) evaluations should be documented in that scorecard before scale-up quantities are requested. Internal requisition for CJC-1295 (no DAC) should attach the product URL, exact specification (5mg / 10mg), and intended Growth Research protocol reference. Procurement teams that paraphrase mg strength often trigger QA holds because vial labels and COA fields use fixed notation from the catalog.
When principal investigators first approve CJC-1295 (no DAC) for a study, they typically map mechanism literature to the SKU listed under Growth Research. The overview section “What is CJC-1295 (no DAC)?” on sulanpeptide.vip helps teams confirm the peptide class before purchase—not as protocol guidance, but as a specification cross-check. International buyers ordering CJC-1295 (no DAC) should confirm import rules for research peptides in the destination country before payment. Include destination, quantity, and required documentation (COA, Janoshik if applicable) in the first quote message to avoid shipment delays.
Repeat procurement of CJC-1295 (no DAC) across study phases benefits from lot continuity notes in reorder emails. If migration or receptor assays compare batches, record prior lot numbers alongside primary data so variability can be traced to material rather than technique.
CJC-1295 (no DAC) from Sulan Peptide Official is for research use only (RUO)—not for human or veterinary use. Questions: Contact page or WhatsApp on sulanpeptide.vip.